Competition???, page-45

Thanks Chel6888, you have been busy with your recent PAR and competitor research!

Yes products like CNTX-4975 are showing some effectiveness in terms of pain relief. it is an intra articular injection but may only be required in some patients every 24 weeks or so which isn't too bad. It really only offers pain relief in individual joints so could be a viable solution in this realm at some point in the future.

The wonderful thing about our iPPS is that it may only be a once a year treatment for us, it is to be taken subcutaneously thus isn't as onerous as an intraarticular route but the best thing:

We are showing to be DMOAD in many cases, at least to some effect, subject to ongoing studies! There could also be other benefits like the positive effects on blood pressure and reduction in an overall inflammatory sense.

There indeed is a vast difference between temp. pain relief and any slowing, halting and of course regression of the progress of OA.

Depending on the dosing of CNTX-4975, there are some AE's being observed.


The OA and certainly pain and inflammation markets are enormous which bodes well for us even if there is viable competition in this area one day in the future.


DYOR